Business Information
The group's principal activities are carried out through three segments: human health, bioproducts and biopharma. The human health consists of pharmaceutical ingredients derived from organic chemistry. The bioproducts consists of cell culture products, endotoxin detection products, electrophoresis and chromatography products, and contract biopharmaceutical manufacturing services at clinical and commercial scale for the biotechnology and pharmaceutical industries. The biopharma consists ofgroup's contract biopharmaceutical process development and manufacturing business. Trademarks include poietics(tm) , clonetics(R), seaplaque(R), nusieve(R), reliant(R), latitude(R), pager(R), metaphor(R), accugene(R) and biowhittaker(tm). During the year 2003 the group discontinued rutherford chemicals segment.
|
|
Name |
Title
|
Email
|
| James Mack | Chmn., CEO, Pres. | N/A | | Paolo Russolo | Pres. - Profarmaco Milano | N/A | | Greg Sargen | CFO, VP | Available | | Jonathan Knight | VP - Sales, Europe | N/A | | Nicholas Shackley | VP - Sales, Business Development, North America | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 455,474 | (30,100) | | 2005 | 455,097 | (110,458) | | 2004 | 443,657 | (26,870)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
